Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials

The clinical contract research organization (CRO) ICRC-Weyer GmbH, based in Berlin, Germany, has announced that the company is prepared for the increasing number of Advanced Therapy trials, a trend that is expected to continue for the next 10 to 15 years.

(firmenpresse) - ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in discussions on potential co-operations with other participants.

The event demonstrated the rapid and versatile development in the area of regenerative medicine. One of the attendees, Dr. Iris Hardewig, Head of Medical Writing & Scientific Consulting at ICRC-Weyer GmbH, said: ‘Due to new regulations in the field of Advanced Therapy Medicinal Products (ATMP) a wave of registrations for such can be expected in the coming 10 to 15 years. Hence, the number of clinical trials for these products will increase significantly. As a medium-sized CRO providing specialized and flexible services to small biotech companies, ICRC-Weyer can deliver high-quality results for ATMP trials and contribute to this promising development.’

Just recently, ICRC-Weyer announced that the company has extended its clinical monitoring services portfolio to monitoring for trials in the area of stem cell research and thus being able to serve the demands of the global pharmaceutical industry in the growing field of regenerative medicine.

‘The engaged discussions of our team members with different participating companies show that there is a lively interest in high quality clinical services in the area of regenerative medicine’, Dr. Hardewig continues, ‘one reason being the initiation of the 7th Framework Programme (FP7) by the EU which provides an important source for funding early clinical development of advanced therapies. The program has paved the way for further research in Europe in the area of ATMP.’

About the NanoKTN event:

The networking event was hosted by UK Nanotechnology Knowledge Transfer Network (NanoKTN) and BioTOP Berlin-Brandenburg. The meeting is designed to bring a selection of the UK’s leading companies and academics developing nano-structured materials and biomaterials for use in tissue engineering and regenerative medicine, to meet with centres of research excellence in Berlin.

About FP7:
The Seventh Framework Programme for Research and Technological Development (FP7) is the EU's main instrument for funding research in Europe. The program supports research in selected priority areas - the aim being to make, or keep, the EU as a world leader in those sectors.

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: icrc_weyer
Datum: 25.09.2012 - 16:50 Uhr
Sprache: Deutsch
News-ID 186587
Anzahl Zeichen: 2972

contact information:

Kategorie:

Pharmaceuticals & Biotech

Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Date of sending: 25.09.2012

Diese Pressemitteilung wurde bisher 361 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials"
steht unter der journalistisch-redaktionellen Verantwortung von

ICRC-Weyer GmbH (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies ...

In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing. ‘Our pharmacovigilance ...

ICRC-Weyer To Boost Drug Safety Services For Investigator Trials ...

An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to la ...

ICRC-Weyer Joins CDISC®, Expands Data Management ...

As part of a continuous growth process, ICRC-Weyer has added further members to its data management team enabling the company to meet the increasing demand for a complete range of services for phase I-IV clinical trials as well as post-marketing stud ...

Alle Meldungen von ICRC-Weyer GmbH